You are here: Industry Insights > OSE

News List

Alexis Peyroles Departs OSE Immunotherapeutics as CEO contractpharma
January 17, 2022
OSE Immunotherapeutics SA has announced the departure of Alexis Peyroles as chief executive officer.
First patient dosed with multi-variant second-generation COVID-19 vaccine europeanpharmaceuticalreview
May 28, 2021
The first-in-human trial of OSE Immunotherapeutics’ multi-variant, second-generation COVID-19 vaccine has enrolled and dosed its first participant.
OSE Immunotherapeutics Expands Collaboration with MAbSilico americanpharmaceuticalreview
February 05, 2021
OSE Immunotherapeutics announced a new collaboration agreement with MAbSilico, a deep technology TechBio located in Tours, France, to use artificial intelligence (AI)-based software for therapeutic monoclonal antibody drug development.
OSE’s Covid-19 vaccine shows promise in preclinical studies pharmaceutical-technology
August 18, 2020
OSE Immunotherapeutics has reported positive data from preclinical and human ex-vivo studies of its Covid-19 vaccine candidate, CoVepiT.
OSE Immunotherapeutics Announces Positive Results from Antagonist OSE-127 Study americanpharmaceuticalreview
December 30, 2019
OSE Immunotherapeutics announced completion and positive results from the Phase 1 study of OSE-127, a humanized monoclonal antibody with a differentiated mechanism of action ...
OSE Immunotherapeutics, HalioDx Announce Lung Cancer Study Collaboration americanpharmaceuticalreview
December 30, 2019
OSE Immunotherapeutics and HalioDx announced a collaboration to conduct a translational investigation of immune biomarkers as part of the ongoing Phase 3 clinical trial of ...
Boehringer Ingelheim and OSE Immunotherapeutics Announce Dosing Of the First Patient in a Phase 1 Trial of SIRPα Antagonist Monoclonal Antibody, BI 765063, in Patients with Advanced Solid Tumors drugs
June 19, 2019
Boehringer Ingelheim and OSE Immunotherapeutics Announce Dosing Of the First Patient in a Phase 1 Trial of SIRPα Antagonist Monoclonal Antibody, BI 765063, in Patients with Advanced Solid Tumors.
OSE Immunotherapeutics Announces New Research Collaboration with Léon Bérard Cancer Center to Use Artificial Intelligence Technologies pharmafocusasia
March 28, 2019
OSE Immunotherapeutics, announces a new research collaboration agreement with premier cancer research hospital, Léon Bérard Cancer Center in Lyon, France, to use artificial intelligence (AI)-based bioanalysis and bioinformatics to identify novel targets i
BI snaps up OSE’s novel checkpoint inhibitor pharmatimes
July 18, 2018
Boehringer Ingelheim and OSE Immunotherapeutics have joined forced to develop OSE-172, a novel checkpoint inhibitor antibody targeting myeloid lineage cells for the treatment of advanced solid tumours.